Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Astellas Pharma : , City of Yokohama, and Yokohama City University Developed Science-Based Exercise Programs through Industry-Government-Academia Collaboration

06/05/2020 | 08:49am EST

TOKYO - Astellas Pharma Inc. (Tokyo, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') developed science-based exercise programs in cooperation with the City of Yokohama, Kanagawa Prefecture (Kanagawa, Mayor: Fumiko Hayashi, 'City of Yokohama') and Yokohama City University (Kanagawa, Chairperson of the Board of Trustees and CEO: Yoshiyuki Futami, 'YCU').

Exercise therapy is reported to be beneficial to patients with type 2 diabetes, and the Japanese Clinical Practice Guidelines for Diabetes 2019 issued by the Japan Diabetes Society indicates that 'exercise therapy consisting of aerobic exercise, resistance exercise, or combination of the two improves blood glucose control and risk factors for cardiovascular disease in patients with type 2 diabetes.' Therefore, there was a need for the development of scientific evidence to support the specific instruction of effective exercise therapies by way of detailed exercise programs and implementation methods for diabetes patients or how to implement them.

Astellas has been aiming to develop science-based exercise programs for exercise therapies for patients with type 2 diabetes by combining Astellas' strength cultivated through its ethical pharmaceutical business practices, and technology and knowledge from different fields through industry-government-academia collaboration with City of Yokohama and YCU. We have designed an exercise program combining aerobic exercise with resistance exercise (repetitive exercises that exert resistance on target muscles) and confirmed the clinical utility of this exercise program in improving blood glucose control in a medical and health research conducted in Japan (an exercise intervention study with a control group).

In the development of this exercise program, Astellas was responsible for designing the exercise program, in addition to planning and implementing the medical and health research. Yasuo Terauchi, Professor, Association of Medical Science Department of Endocrinology and Metabolism, Yokohama City University participated in this program upon introduction by the Life Innovation Platform YOKOHAMA (LIP. Yokohama1 ) as a medical and health research expert essential to development.

Astellas plans to make these science-based exercise programs available through fitness clubs starting with limited areas in Japan in 2020. Astellas will continue to pursue the creation of societies where people can live mentally and physically healthy lives and be true to themselves, by creating and providing evidence-based healthcare solutions through the integration of medicine and exercise.

About LIP. Yokohama

Life Innovation Platform YOKOHAMA (LIP. Yokohama) is designed to help the City of Yokohama collaborate with the industry, academic, government, and financial institutions in order to provide continual support for innovation in the health & medical fields in Yokohama. Through this platform, a network of enterprises, universities, and research institutes develops innovative projects. At the same time, LIP. Yokohama supports the commercialization of small, medium-sized, and venture enterprises and promotes the development of new technologies and products. LIP. Yokohama is available through its website at https://www.city.yokohama.lg.jp/business/keizai/lifescience/lip/lifepf.html

About Yokohama City University

Located in the international city of Yokohama, Yokohama City University has 5 campuses, 5 faculties, 6 graduate schools, 2 affiliated research centers, and 2 affiliated hospitals that serve as the bases for education, research, and medical care. Yokohama City University is available through its website at https://www.yokohama-cu.ac.jp/en/

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit our website at https://www.astellas.com/en

Cautionary Notes (Astellas)

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Astellas Pharma Inc.

Corporate Advocacy & Relations

TEL: +81-3-3244-3201

FAX: +81-3-5201-7473

Yokohama City University

Research Planning and University-Industry Cooperation Division


City of Yokohama

Business Alliance Promotion Division

Innovation City Promotion Department

Economic Affairs Bureau

TEL: +81-45-671-2574

E-mail: ke-lifePF@city.yokohama.jp

(C) 2020 Electronic News Publishing, source ENP Newswire

01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
2020Japanese shares slip back as investors look to U.S. stimulus debate
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
More news
Sales 2021 1 269 B 12 216 M 12 216 M
Net income 2021 185 B 1 776 M 1 776 M
Net cash 2021 440 B 4 234 M 4 234 M
P/E ratio 2021 16,5x
Yield 2021 2,53%
Capitalization 3 087 B 29 742 M 29 710 M
EV / Sales 2021 2,09x
EV / Sales 2022 1,90x
Nbr of Employees 15 883
Free-Float 99,2%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 662,00 JPY
Spread / Highest target 117%
Spread / Average Target 36,5%
Spread / Lowest Target -0,72%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993